99mtc-trodat-1 spect in healthy and 6-ohda lesioned parkinsonian monkeys: comparison with f-fdopa pet

Nuclear Medicine Communications

Volumn 24, Issue 1, 2003, Pages 77-83

  Huang, W S ^a   MA, K H ^a   Chou, Y H ^b   Chen, C Y ^b   Liu, R S ^b   Liu, J C ^b  

^a Biology and Anatomy and Psychiatry   (United States)

^b TRI SERVICE GENERAL HOSPITAL   (Taiwan)

Author keywords

19mTc TRODAT 1 SPECT; F FDOPA PET; Parkinsonian monkey

Indexed keywords

DIAGNOSTIC AGENT; DOPA; DRUG DERIVATIVE; FLUORODOPA F 18; OXIDOPAMINE; RADIOPHARMACEUTICAL AGENT; TECHNETIUM COMPLEX; TECHNETIUM TC 99M TRODAT 1; TECHNETIUM TC 99M TRODAT-1; TROPANE DERIVATIVE;

ANIMAL; ANIMAL MODEL; ARTICLE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORPUS STRIATUM; EVALUATION; MACACA; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PARKINSONISM; REFERENCE VALUE; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; VALIDATION STUDY;

ANIMALS; CORPUS STRIATUM; DIHYDROXYPHENYLALANINE; MACACA; METABOLIC CLEARANCE RATE; MODELS, ANIMAL; ORGANOTECHNETIUM COMPOUNDS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RADIOPHARMACEUTICALS; REFERENCE VALUES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 85047278701     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200301000-00018     Document Type: Article

References (37)

1. Kollwe WC, Langston JW, Hubble JP, et al. Does a long pre-clinical period occur in Parkinson's disease. Neurology 1991; 41(Suppl. 2): 8-13.
2. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967; 17: 427-442.
3. Hughes AJ, Daniel SE, Kilford L, Lee AJ. The accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinicopathological study. J Neurol Neurosurg Psychiatry 1992; 55: 181-184.
4. 123I]β-CIT SPECT visualizes dopamine transporter loss in de novo Parkinson patients. Eur Neurol 1998; 39: 44-48.
5. Agid Y. Parkinson's disease: pathophysiology. Lancet 1991; 337: 1321-1324.
6. Koller WC. How accurately can Parkinson's disease be diagnosed. Neurology 1992; 42: 6-16.
7. Nirenberg MJ, Vaughan RA, Uhl GR, Kuhar MJ, Pickel VM. The dopamine transporter is localized to dendritic and axonal plasma membranes of nigrostriatal dopaminergic neurons. J Neurosci 1996; 16: 436-447.
8. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in striatum of patients with idiopathic Parkinson's disease. N Engl J Med 1988; 876: 876-880.
9. Kaufman MJ, Madras BK. Severe depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson's-diseased striatum. Synapse 1991; 9: 43-49.
10. 123I]β-CIT binding and SPET compared with clinical diagnosis in parkinsonism. Nucl Med Comm 2000; 21: 417-424.
11. Seibyl JP, Marek KL, Quinlan D, et al. Decreased single-photon emission tomographic [I-123]β-CIT SPECT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995; 38: 589-598.
12. Marek KL, Seibyl JP, Zoghbi SS, et al. [I-123]β-CIT SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996; 46: 231-237.
13. Shaya EK, Scheffel U, Dannals RF, et al. In vivo imaging of dopamine reuptake sites in the primate brain using SPECT and I-123 labeled RTI-55. Synapse 1992; 10: 169-172.
14. Fischman AJ, Babich JW, Elmaleh DR, et al. SPECT imaging of dopamine transporter sites in normal and MPTP-treated rhesus monkeys. J Nucl Med 1997; 38: 144-150.
15. 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993; 34: 423-431.
16. 11C]RTI-32 PET studies of the dopamine transporter in early dopamine-naïve Parkinson's disease: implications for the symptomatic threshold. Neurology 1997; 48: 1578-1583.
17. Booij J, Tissingh G, Winogrodzka A, van Royen EZ. Imaging of the dopaminergic neurotransmission system using single-photon emission tomography and positron emission tomography in patients with parkinsonism. Eur J Nucl Med 1999; 26: 171-182.
18. 99mTc. J Nucl Med 1997; 38: 100p.
19. Meltzer PC, Blundell P, Jones AG, et al. A technetium-99m SPECT imaging agent which targets the dopamine transporter in primate brain. J Med Chem 1997; 40: 1835-1844.
20. Kung HF, Kim JH, Kung MP, Meegalla SK, Plössl K, Lee HK. Imaging of dopamine transporters in human with technetium-99m TRODAT-1. Eur J Nucl Med 1996; 23: 1527-1530.
21. 99mTc]TRODAT-1 in hemi-parkinsonism rat brain. Nucl Med Biol 2001; 28: 923-928.
22. 123I]IBZM in normal and 6-OHDA-lesioned formosan rock monkeys. Nucl Med Biol 2002; 29: 561-567.
23. 99mTc TRODAT-1. Eur J Nucl Med 1998; 25(Suppl.): 1164.
24. 18F] fluoro-L-FDOPA for dopaminergic function imaging with PET. Ann Nucl Med Sci 1999; 12: 1-6.
25. 99mTc]TRODAT-1: a dopamine transporter imaging agent. J Nucl Med 1999; 40: 150-158.
26. 99mTc TRODAT-1: a novel technetium-99m complex as dopamine tranporter imaging agent. Eur J Nucl Med 1997; 24: 372-380.
27. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994; 57: 672-681.
28. Quinn N. Multiple system atrophy - the nature of the beast. J Neurol Neurosug Psychiatry 1989; 52(Suppl.): 78-89.
29. Henwood J. Selegiline for Parkinson's disease. Med Prog 1998; June: 44-45.
30. Aquilonius SM, Bergstrom K, Eckernan SA, et al. In vivo evaluation of striatal dopamine reuptake sites using C-11-nomifensine and PET. Acta Neurol Scand 1987; 76: 283-287.
31. Kilbourn MR, Carey JE, Koeppe RA, et al. Biodistribution, dosimetry, metabolism and monkey PET studies of [F-18]GBR 13119 imaging the dopamine uptake system in vivo. Nucl Med Biol 1989; 16: 569-576.
32. Eidelberg D, Moeller JR, Ishikawa T, et al. Early differential diagnosis of Parkinson's disease with F-18-FDG and PET. Neurology 1995; 45: 1995-2004.
33. Innis RB, Seibyl JB, Scanley BE, et al. Single photon computed imaging demonstrates loss of striatal dopamine transporters in Parkinson's disease. Proc Natl Acad Sci USA 1993; 90: 11965-11969.
34. Ishikawa T, Dhawan V, Kazumata K, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-βCIT-FP SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996; 37: 1760-1765.
35. Wilson JM, Levey AI, Rajput A, et al. Differential changes in neurochemical markers of striatal dopsmine nerve terminals in iodiopathic Parkinson's disease. Neurology 1996; 47: 718-726.
36. Torstenson R, Hartvig P, Langstrom B, Westerberg G, Tedroff J. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol 1997; 41: 334-340.
37. 99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000; 41: 584-589.